The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide
Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impai...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 19 2010
|
| In: |
Onkologie
Year: 2010, Jahrgang: 33, Heft: 4, Pages: 183-186 |
| ISSN: | 1423-0240 |
| DOI: | 10.1159/000286447 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1159/000286447 Verlag, lizenzpflichtig, Volltext: https://karger.com/onk/article-abstract/33/4/183/247593/The-Oral-Histone-Deacetylase-Inhibitor-LBH589-Is-a 
|
| Verfasserangaben: | Stefan Schmitt, Anthony D. Ho, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1848968736 | ||
| 003 | DE-627 | ||
| 005 | 20230710130814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230614s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000286447 |2 doi | |
| 035 | |a (DE-627)1848968736 | ||
| 035 | |a (DE-599)KXP1848968736 | ||
| 035 | |a (OCoLC)1389793877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schmitt, Stefan |d 1976- |e VerfasserIn |0 (DE-588)130521914 |0 (DE-627)503037680 |0 (DE-576)190007168 |4 aut | |
| 245 | 1 | 4 | |a The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide |c Stefan Schmitt, Anthony D. Ho, Hartmut Goldschmidt |
| 264 | 1 | |c March 19 2010 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.06.2023 | ||
| 520 | |a Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impairment. LBH589 is a histone deacetylase inhibitor with an epigenetic mechanism of action and the potential for treatment in myeloma. We report here about the successful treatment of a 44-year-old woman suffering from progressive myeloma with LBH589 after five different chemotherapies. During the 9 years after first diagnosis of myeloma in April 2000, our patient twice underwent an autologous stem cell transplantation and was also treated with the new substances bortezomib, thalidomide and lenalidomide. | ||
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Onkologie |d Basel : Karger, 1978 |g 33(2010), 4 vom: Apr., Seite 183-186 |h Online-Ressource |w (DE-627)300595417 |w (DE-600)1483097-8 |w (DE-576)105282863 |x 1423-0240 |7 nnas |a The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide |
| 773 | 1 | 8 | |g volume:33 |g year:2010 |g number:4 |g month:04 |g pages:183-186 |g extent:4 |a The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000286447 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://karger.com/onk/article-abstract/33/4/183/247593/The-Oral-Histone-Deacetylase-Inhibitor-LBH589-Is-a |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230614 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 3 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 130521914 |a Schmitt, Stefan |m 130521914:Schmitt, Stefan |d 910000 |d 910100 |e 910000PS130521914 |e 910100PS130521914 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1848968736 |e 4336965285 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 15.12.2023"],"id":{"eki":["300595417"],"zdb":["1483097-8"],"issn":["1423-0240"]},"part":{"year":"2010","pages":"183-186","volume":"33","text":"33(2010), 4 vom: Apr., Seite 183-186","extent":"4","issue":"4"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"international journal for cancer research and treatment","title_sort":"Onkologie","title":"Onkologie"}],"origin":[{"publisherPlace":"Basel","dateIssuedKey":"1978","dateIssuedDisp":"1978-2013","publisher":"Karger"}],"pubHistory":["1.1978 - 36.2013"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger"],"disp":"The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomideOnkologie","recId":"300595417"}],"note":["Gesehen am 14.06.2023"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1159/000286447"],"eki":["1848968736"]},"physDesc":[{"extent":"4 S."}],"language":["eng"],"title":[{"title_sort":"oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide","title":"The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide"}],"recId":"1848968736","origin":[{"dateIssuedDisp":"March 19 2010","dateIssuedKey":"2010"}],"name":{"displayForm":["Stefan Schmitt, Anthony D. Ho, Hartmut Goldschmidt"]},"person":[{"display":"Schmitt, Stefan","given":"Stefan","family":"Schmitt","role":"aut"},{"role":"aut","family":"Ho","display":"Ho, Anthony Dick","given":"Anthony Dick"},{"role":"aut","display":"Goldschmidt, Hartmut","given":"Hartmut","family":"Goldschmidt"}]} | ||
| SRT | |a SCHMITTSTEORALHISTON1920 | ||